<DOC>
	<DOCNO>NCT00970892</DOCNO>
	<brief_summary>The investigator aim use pharmacogenetic information clinical practise may lead rapid , efficient , safe warfarin dose observational prospective study . In context , investigator plan develop algorithm estimate appropriate warfarin dose base clinical genetic data Turkish study population . This study unique investigate clinical factor , demographic variable , CYP2C9 , VKORC1 gene variation contribute variability among patient dose requirement warfarin also include thrombogenic single nucleotide polymorphism ( SNP ) patient population . Thus , warfarin would good example first cardiovascular drug pharmacogenetic guide `` personalized medicine '' application .</brief_summary>
	<brief_title>VKORC1 CYP2C9 Gene Polymorphisms Warfarin Management</brief_title>
	<detailed_description>Long-term anticoagulation therapy warfarin recommend patient atrial fibrillation/flutter ( AF ) , leave atrial thrombus , deep vein thrombosis ( DVT ) , pulmonary thromboembolism ( PE ) , mechanical heart valve replacement , cardiomyopathy , ischemic stroke . Warfarin , coumarin derivative , produce anticoagulant effect interfere vitamin K 2,3 epoxide reductase ( VKOR ) enzyme Î³-carboxylation vitamin K-dependent clotting factor II , VII , IX , X . However , management warfarin therapy complicate interindividual difference drug response , delay onset action , difficulty reversal narrow therapeutic window lead increase risk life-threatening hemorrhagic adverse event thromboembolism . Furthermore , order determine safe effective loading dose early phase therapy maintenance dos require frequent laboratory monitoring adjustment compensate change patient ' age , body size , vitamin K intake diet , disease state , comorbidities , concomitant use medication , patient-specific genetic factor . Poor anticoagulant control may cause fatal complication thromboembolism undertreatment bleed excessive anticoagulation . Indeed , risk major bleed patient warfarin 1 % 5 % per year . Identifying optimal therapeutic range manage dose therapy achieve maximal time therapeutic range two important determinant therapeutic effectiveness reduce hemorrhagic risk . Currently , substantial effort improve safety warfarin anticoagulation therapy . Recent warfarin pharmacogenetic study largely focus two candidate gene : CYP2C9 , responsible warfarin metabolism , VKORC1 , encode vitamin K epoxide reductase , site warfarin action . Current evidence clear polymorphism either CYP2C9 VKORC1 affect warfarin sensitivity . We aim use pharmacogenetic information clinical practise may lead rapid , efficient , safe warfarin dose observational prospective study . In context , plan develop algorithm estimate appropriate warfarin dose base clinical genetic data Turkish study population . This study unique investigate clinical factor , demographic variable , CYP2C9 , VKORC1 gene variation contribute variability among patient dose requirement warfarin also include thrombogenic single nucleotide polymorphism ( SNP ) patient population . Thus , warfarin would good example first cardiovascular drug pharmacogenetic guide `` personalized medicine '' application .</detailed_description>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Cardiomyopathies</mesh_term>
	<mesh_term>Embolism</mesh_term>
	<mesh_term>Vascular Diseases</mesh_term>
	<mesh_term>Pulmonary Embolism</mesh_term>
	<mesh_term>Venous Thrombosis</mesh_term>
	<mesh_term>Peripheral Vascular Diseases</mesh_term>
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Warfarin</mesh_term>
	<criteria>Patients require warfarin least 6 month indication list : Permanent Atrial Fibrillation/Flutter Left atrial ventricular thrombus Deep Vein Thrombosis Pulmonary Embolism Heart Valve Replacement ( Mechanical Biological With AF ) Cardiomyopathy ( Ischemic Dilated ) Peripheral Vascular Disease History GI bleed peptic ulcer disease Significant liver disease , active hepatitis chronic HBV/HCV infection Uncontrolled hypertension Chronic diarrhea malabsorption syndrome Viral bacterial infection prior enrollment Active previous infective endocarditis Hospital stay &gt; 30 day result septicemia , mediastinitis pneumonia Cardiac cachexia Morbid obesity Expected pregnancy , pregnancy lactation Psychiatric disease Malignancy Life expectancy less 1 year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>Anticoagulation</keyword>
	<keyword>warfarin</keyword>
	<keyword>VKORC1</keyword>
	<keyword>CYP2C9</keyword>
	<keyword>thromboembolism</keyword>
	<keyword>pharmacogenetics</keyword>
</DOC>